news
FDA approves Abecma, the first cell-based gene therapy for adults with multiple myeloma
Abecma (idecabtagene vicleucel) was approved for adults with relapsed or refractory myeloma based on its 72 percent overall response rate in a trial.
List view / Grid view
Anti-Cancer Therapeutics
news
Machine learning used to predict most effective cancer drugs
According to a new study, Drug Ranking Using Machine Learning (DRUML) can accurately rank cancer therapies by efficacy across a range of cancer types.
news
Novel radionuclide therapy found to be more effective in NET patients
The study shows modifying the standard of care for late-stage neuroendocrine tumours (NETs) with Evans blue dye makes the treatment more effective and potentially less toxic.
news
Using albumin could facilitate vaccination by inhalation, finds pre-clinical study
MIT researchers developed and tested in mice intratracheal vaccines to protect against the vaccinia virus and the formation of lung cancer.
article
How has COVID-19 impacted the development of cell and gene therapies?
European Pharmaceutical Review’s Hannah Balfour explores the findings of the Cell and Gene Therapy (CGT) Catapult’s 2020 advanced therapy medicinal product trials report and discusses how the European and global CGT markets are expected to perform in coming years.
news
NICE approves olaparib and bevacizumab for use on the Cancer Drugs Fund
The recommendation will allow more data to be collected about the combination treatment while allowing patients with high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer to access the medication.
news
NICE recommends new triple therapy treatment for multiple myeloma
Carfilzomib with dexamethasone and lenalidomide could be offered to approximately 2,000 NHS patients as a second line treatment for multiple myeloma.
news
New oral chronic lymphocytic leukaemia treatment made available on NHS
AstraZeneca’s Calquence (acalabrutinib), a chemotherapy-free monotherapy, will be offered to patients with chronic lymphocytic leukaemia.
news
CRISPR therapies could be one of the most transformative in human history, says GlobalData
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.
news
Libtayo® improves overall survival in advanced cervical cancer patients
A Phase III trial evaluating Libtayo® (cemiplimab) monotherapy in advanced cervical cancer has been stopped early due to a positive result on overall survival.
news
UK conditionally approves Lilly’s Retsevmo® for RET-driven lung and thyroid cancers
The conditional marketing authorisation of Retsevmo® (selpercatinib) was based on positive results from the LIBRETTO-001 Phase I/II trial.
news
QUZYTTIR™ shows promise in preventing infusion related reactions
Phase II data suggests intravenous QUZYTTIR™ cetirizine hydrochloride can decrease infusion reactions to anti-CD20 antibody treatments and reduce time to discharge after therapy.
news
First person enrolled in Phase I oncolytic virus trial
The Phase I/IIa trial of BT-001 will assess the safety and efficacy of the virus’ dual mode of action in solid tumours.
news
Launch of generic oncology medications to improve treatment access in India
GlobalData suggests the recent approval of new generics in oncology should enhance access and adherence to cancer treatment by reducing costs borne by patients.
news
EMA recommends six medications for approval in February meeting
The EMA’s committee adopted positive opinions of six medications, including two orphan drugs, and concluded its review of the use of REGN-COV2 – an investigational antibody therapy for COVID-19.
